Bone Biologics Corp Warrants
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology use… Read more
Bone Biologics Corp Warrants (BBLGW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.070x
Based on the latest financial reports, Bone Biologics Corp Warrants (BBLGW) has a cash flow conversion efficiency ratio of -0.070x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-458.88K) by net assets ($6.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bone Biologics Corp Warrants - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Bone Biologics Corp Warrants's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bone Biologics Corp Warrants Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bone Biologics Corp Warrants ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elon AB (publ)
ST:ELON
|
0.175x |
|
Urbanise.com Ltd
AU:UBN
|
0.336x |
|
Foodlink A.E
AT:FOODL
|
1.036x |
|
Bastas Baskent Cimento Sanayi ve Ticaret AS
IS:BASCM
|
0.160x |
|
UTStarcom Holdings Corp
NASDAQ:UTSI
|
-0.054x |
|
Transcode Therapeutics Inc
NASDAQ:RNAZ
|
-0.003x |
|
Digital Graphics Incorporation
KQ:043360
|
0.027x |
|
Seamless Distribution Systems AB
ST:SDS
|
-0.126x |
Annual Cash Flow Conversion Efficiency for Bone Biologics Corp Warrants (2012–2024)
The table below shows the annual cash flow conversion efficiency of Bone Biologics Corp Warrants from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.48 Million | $-4.12 Million | -1.184x | +63.99% |
| 2023-12-31 | $2.91 Million | $-9.56 Million | -3.288x | -448.21% |
| 2022-12-31 | $5.95 Million | $-3.57 Million | -0.600x | -220.99% |
| 2021-12-31 | $6.58 Million | $-1.23 Million | -0.187x | -699.23% |
| 2020-12-31 | $-13.69 Million | $-426.93K | 0.031x | -88.62% |
| 2019-12-31 | $-11.87 Million | $-3.25 Million | 0.274x | -42.62% |
| 2018-12-31 | $-8.60 Million | $-4.10 Million | 0.477x | +20.37% |
| 2017-12-31 | $-8.40 Million | $-3.33 Million | 0.397x | -53.27% |
| 2016-12-31 | $-8.63 Million | $-7.33 Million | 0.849x | +35.98% |
| 2015-12-31 | $-5.68 Million | $-3.55 Million | 0.624x | -16.23% |
| 2014-12-31 | $-3.70 Million | $-2.76 Million | 0.745x | +68218.73% |
| 2013-12-31 | $-5.61 Million | $-6.12K | 0.001x | -98.86% |
| 2012-12-31 | $-4.68K | $-447.00 | 0.096x | -- |